Breaking News, Collaborations & Alliances

CANbridge, WuXi Biologics Expand Partnership

Their rare disease partnership will enable CANbridge to discover, develop and commercialize four additional drug candidates

CANbridge Pharmaceuticals and WuXi Biologics jointly announced an expansion of their rare disease partnership to enable CANbridge to discover, develop and commercialize four additional drug candidates.  These new candidates target rare genetic chronic diseases. According to the agreement, CANbridge has an exclusive regional or global rights for these therapies. WuXi Biologics will receive upfront, milestone payments and royalties. WuXi Biologics will also be the exclusive clinical supplier a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters